Abstract

Cyclic GMP phosphodiesterase (PDE) is an essential component in retinal phototransduction. PDE is regulated by Pgamma, the regulatory subunit of PDE, and GTP/Talpha, the GTP-bound alpha subunit of transducin. In previous studies (Tsuboi, S., Matsumoto, H. , Jackson, K. W., Tsujimoto, K., Williamas, T., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15016-15023; Tsuboi, S., Matsumoto, H., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15024-15029), we showed that Pgamma is phosphorylated by a previously unknown kinase (Pgamma kinase) in a GTP-dependent manner in photoreceptor outer segment membranes. We also showed that phosphorylated Pgamma loses its ability to interact with GTP/Talpha, but gains a 10-15 times higher ability to inhibit GTP/Talpha-activated PDE than that of nonphosphorylated Pgamma. Thus, we propose that the Pgamma phosphorylation is probably involved in the recovery phase of phototransduction through shut off of GTP/Talpha-activated PDE. Here we demonstrate that all known Pgammas preserve a consensus motif for cyclin-dependent protein kinase 5 (Cdk5), a protein kinase believed to be involved in neuronal cell development, and that Pgamma kinase is Cdk5 complexed with p35, a neuronal Cdk5 activator. Mutational analysis of Pgamma indicates that all known Pgammas contain a P-X-T-P-R sequence and that this sequence is required for the Pgamma phosphorylation by Pgamma kinase. In three different column chromatographies of a cytosolic fraction of frog photoreceptor outer segments, the Pgamma kinase activity exactly coelutes with Cdk5 and p35. The Pgamma kinase activity ( approximately 85%) is also immunoprecipitated by a Cdk5-specific antibody, and the immunoprecipitate phosphorylates Pgamma. Finally, recombinant Cdk5/p35, which were expressed using clones from a bovine retina cDNA library, phosphorylates Pgamma in frog outer segment membranes in a GTP-dependent manner. These observations suggest that Cdk5 is probably involved in the recovery phase of phototransduction through phosphorylation of Pgamma complexed with GTP/Talpha in mature vertebrate retinal photoreceptors.

Highlights

  • Cyclic GMP phosphodiesterase (PDE) is an essential component in retinal phototransduction

  • It has been believed that cGMP binding to noncatalytic sites on mammalian P␣␤ is not regulated by P␥, because the cGMP binding to P␣␤ has been shown to be very tight [23]

  • We found that the P␥ mutant in which threonine 22 was replaced by valine (T22V) was not phosphorylated by P␥ kinase; the P␥ mutant in which threonine 35 was substituted by valine (T35V) was phosphorylated (Fig. 1)

Read more

Summary

Introduction

Cyclic GMP phosphodiesterase (PDE) is an essential component in retinal phototransduction. Recombinant Cdk5/p35, which were expressed using clones from a bovine retina cDNA library, phosphorylates P␥ in frog outer segment membranes in a GTP-dependent manner These observations suggest that Cdk is probably involved in the recovery phase of phototransduction through phosphorylation of P␥ complexed with GTP/T␣ in mature vertebrate retinal photoreceptors. Amphibian P␥ functions as an inhibitor of cGMP hydrolysis by P␣␤ and as a stimulator of cGMP binding to noncatalytic sites on P␣␤ These functionally different P␥s appear to be released by GTP/T␣ in different steps of phototransduction [16]. A crucial point of this P␥ phosphorylation is that P␥ complexed with GTP/T␣ is the best substrate for P␥ kinase and that P␥ kinase phosphorylates P␥ in ROS membranes in a GTP-dependent manner These observations indicate that the P␥ phosphorylation occurs only after PDE activation. 5-CCTTTCCTGGGGACGACGGGTCCCC-3ЈЈ 5-CCTTTCCTGGGGTCGACGGGTCCC-3Ј Ј 5-CCTTTCCTGGGCTCGACGGGTCCC-3Ј 5-CCTTTCCTGGGCTTGACGGGTCCC-3Ј 5-GAACTGCCTCACTTGCCGCTGC-3Ј 5-GGGAGTGACGCCTCCCCCCATCAC-3Ј 5-CCCTTTCCTGCCAGTGACGGGTCC-3ЈЈ 5-CCCTTTCCTTCCAGTGACCCCTCC-3Ј 5-CCGTCACTCCCAAAAAAGGGCCCCC-3Ј 5-CCGTCACTCCCCACAAAGGGCCCCC-3ЈЈ 5-CCGTCACTCCGGAGAAAGGGCCC-3ЈЈ 5-TCACTCCCAGGATCGGGCCCCCGAA-3ЈЈ 5-TCACTCCCAGGCACGGGCCCCCGAA-3ЈЈ 5-TCACTCCCAGGAGCGGGCCCCCGAA-3ЈЈ a Underlined letters indicate mutation sites. b These mutants have been used previously [30]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.